| OrienX010 / Seven and Eight BioPharma |
NCT04200040: A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients |
|
|
| Recruiting | 2 | 165 | RoW | OrienX010 injection, Recombinant Human GM-CSF Herpes Simplex Virus Injection, Dacarbazine (DTIC) | OrienGene Biotechnology Ltd. | Melanoma (Skin) | 12/22 | 12/22 | | |
OrienX010-II-11, NCT04206358: Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma |
|
|
| Recruiting | 1 | 30 | RoW | OrienX010 combination with JS001, Recombinant Human GM-CSF Herpes Simplex Virus Injection combination with Recombinant Human Anti-PD-1 Monoclonal Antibody Injection | Peking University Cancer Hospital & Institute | Melanoma | 02/21 | 12/23 | | |
| Active, not recruiting | 1 | 33 | RoW | OrienX010 Combination with Toripalimab injection, Recombinant Human GM-CSF Herpes Simplex Virus intratumoral Injection combination with Recombinant Human Anti-PD-1 Monoclonal Antibody infusion | Peking University Cancer Hospital & Institute | Melanoma | 05/21 | 05/25 | | |
| EIK1001 / Eikon Therap |
NCT04819373: BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors |
|
|
| Completed | 2 | 1 | US | BDB001 | Eikon Therapeutics, Seven and Eight Biopharmaceuticals Inc | Tumor, Solid | 04/23 | 05/23 | | |
NCT06246110: A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC |
|
|
| Recruiting | 2 | 70 | US | EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin | Eikon Therapeutics | NSCLC | 12/26 | 12/27 | | |
AGADIR, NCT03915678: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 247 | Europe | Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT | Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics | Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer | 09/24 | 03/26 | | |
| Active, not recruiting | 1 | 50 | US | BDB001, Pembrolizumab | Eikon Therapeutics, Merck Sharp & Dohme LLC | Tumor, Solid | 08/24 | 08/24 | | |
NCT04196530: BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab |
|
|
| Active, not recruiting | 1 | 40 | US | BDB001, Atezolizumab, Tecentriq | Eikon Therapeutics, Seven and Eight Biopharmaceuticals Inc | Tumor, Solid | 07/24 | 07/24 | | |
| BDB018 / Eikon Therap |
KEYNOTE-D26, NCT04840394: Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 1 | US | BDB018, Pembrolizumab | Eikon Therapeutics, Merck Sharp & Dohme LLC | Tumor, Solid | 12/24 | 03/25 | | |
| BDB201 / Seven and Eight BioPharma |
| No trials found |
| BDB030 / Seven and Eight BioPharma |
| No trials found |
| BDB101 / Eikon Therap |
| No trials found |
| BDB102 / Eikon Therap |
| No trials found |
